Skip to main content
. 2015 Apr;11(4 Suppl 2):1–19.

Figure 6.

Figure 6

Patients with adequate relief of global IBS symptoms in TARGET 1 and TARGET 2 during the 10-week follow-up period after cessation of treatment with rifaximin or placebo. IBS, irritable bowel syndrome.

Adapted from Pimentel M et al. N Engl J Med. 2011;364(1):22-32.20